Welcome to CKB CORE's new home! Please be sure to update any bookmarks you may have.
×

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05623319
Title Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) (THOR)
Acronym THOR
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA


No variant requirements are available.